Biography
Prior to joining the King’s Health Economics (KHE) team, Kang completed his MSc in Health Economics and Decision Modelling at University of Sheffield in 2020. He is a Research Associate working on the STARRT-AKI study and Prospects Study at KHE.
The STARRT-AKI trial (https://www.thebottomline.org.uk/summaries/icm/starrt-aki/) is a 7-year multinational clinical trial which aims to compare the cost-effectiveness of accelerated initiation of renal replacement therapy compared to standard initiation in critically ill patients with severe acute kidney injury. He will analyse observational data and other relevant databases (such as Hospital Episode Statistics (HES) data and the Renal registry) to support the development of a de novo simulation (DES) model.
The Prospects trial (https://medphys.royalsurrey.nhs.uk/prospects/) is a 7-year multi-centre clinical trial which aims to explore the cost-effectiveness of breast cancer screening using digital breast tomosynthesis. He will conduct an interim budget impact analysis and adapt an existing economic model for breast cancer screening.
Research Interests
- Health Economic Evaluations (both within-trial and using economic modelling)
- Medical statistics
- Breast cancer
Research
King's Health Economics
King's Health Economics, led by Professor Sarah Byford (Director), and Dr Barbara Barrett (Deputy Director), consists of a team of health economists with expertise in designing and conducting high quality economic evaluations of healthcare programmes and policies that contribute to healthcare policy and practice in the UK and abroad.
Research
King's Health Economics
King's Health Economics, led by Professor Sarah Byford (Director), and Dr Barbara Barrett (Deputy Director), consists of a team of health economists with expertise in designing and conducting high quality economic evaluations of healthcare programmes and policies that contribute to healthcare policy and practice in the UK and abroad.